- Home
- / Edwards Lifesciences
- / Revenue
Edwards LifesciencesHeader placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Annual Revenue ($)
Edwards Lifesciences revenue was $4.39 b in FY, 2020 which is a (0.9%) year over year increase from the previous period.
Quarterly Revenue ($)
Annual Growth Rate (%)
Revenue Breakdown
Business Segment
Geographic Segment
Edwards Lifesciences revenue breakdown by business segment: 65.1% from Transcatheter Aortic Valve Replacement, 17.4% from Surgical Structural Heart, 16.5% from Critical Care and 1.0% from Other
Edwards Lifesciences revenue breakdown by geographic segment: 57.4% from United States, 22.2% from Europe, 10.5% from Japan and 9.9% from Rest of World
| FY, 2019 | FY, 2018 | FY, 2020 | |
|---|---|---|---|
| Transcatheter Mitral and Tricuspid Therapies | $28.2 m | $41.8 m | |
| Transcatheter Aortic Valve Replacement | $2.74 b | $2.86 b | |
| Surgical Structural Heart | $841.7 m | $761.8 m | |
| Critical Care | $740.2 m | $674.5 m | $725.4 m |
| Transcatheter Heart Valve Therapy | $2.29 b | ||
| Surgical Heart Valve Therapy | $761.6 m |
| FY, 2019 | FY, 2018 | FY, 2020 | |
|---|---|---|---|
| United States | $2.53 b | $2.06 b | $2.52 b |
| Europe | $941.2 m | $885.1 m | $973.6 m |
| Japan | $444.7 m | $396.8 m | $460.1 m |
| Rest of World | $429.4 m | $385.6 m | $435.8 m |
Need Data?
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.